Onyx Scientific is planning to broaden its offering to the global pharmaceutical and biotech industries.
The contract manufacturing organisation (CMO) has struck-up a strategic alliance with UK-based Reach Separations, which will allow it to deliver more specialist purification and separation services to bolster its early stage development services.
As part of the deal, Onyx Scientific will be now able to offer custom separation for companies in drug discovery and intermediate environments.
This includes chiral, reverse phase and normal phase chromatography using Supercritical Fluid Chromatography (SFC) and High Performance Liquid Chromatography (HPLC). With MHRA and FDA licensed facilities in the UK and India,
Onyx Scientific supports pharmaceutical and biotech companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.
Reach Separations is located in BioCity in Nottingham, which is one of Europe’s largest bioscience incubators that currently hosts over 70 companies and has a rich heritage in drug discovery.
